BriaCell Therapeutics (BCTX) vs Filana Therapeutics (FLNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BriaCell Therapeutics (BCTX) has outperformed Filana Therapeutics (FLNA) over the past year, losing 69.2% versus a loss of 79.6%. Over five years, BCTX leads with a -95.2% price change compared with -98.4% for FLNA. Filana Therapeutics is the larger company by market cap ($39.3 million vs $34.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | FLNA |
|---|---|---|
| Share price | $3.92 | $0.8136 |
| Market cap | $34.10M | $39.30M |
| 1-day change | -2.00% | -0.26% |
| YTD return | -44.87% | -58.91% |
| 1-year return | -69.18% | -79.56% |
| 5-year return | -95.21% | -98.36% |
| EPS (TTM) | $-0.92 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $4.98 |
| 52-week low | $2.60 | $0.67 |
| Distance from 52-week high | -73.30% | -83.66% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +698.92% |
| Average volume | 278.91K | 2.03M |
| Shares outstanding | 8.70M | 48.31M |
| Employees | — | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCTX has outperformed FLNA by 10.4 percentage points over the past year.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
BCTX vs FLNA FAQ
Which is bigger, BriaCell Therapeutics or Filana Therapeutics?
Filana Therapeutics (FLNA) is larger, with a market capitalization of $39.30M compared with $34.10M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or FLNA?
BCTX returned -69.18% over the past 12 months, compared with -79.56% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and Filana Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.